Long-term follow-up of PI3K delta inhibitor TGR-1202 demonstrates safety and high response rates in NHL: Integrated Analysis of TGR-1202 monotherapy and combined with ublituximab

Drug Category : Array
Conference Category : Array
Lead Author : O'Connor O, et al.
Published Date : 01/06/2016
Download Link : https://www.tgtherapeutics.com/wp-content/uploads/2019/03/EHA%20Integrated%20Analysis%20NHL%20Poster%20FINAL.PDF
Download Text : Download
Popup Confirmation? :
site-sidebar-layout : default
ast-site-content-layout : default
site-content-style : default
site-sidebar-style : default
theme-transparent-header-meta : default
stick-header-meta : default
astra-migrate-meta-layouts : set
Scroll to Top